CLINICAL TRIALS PROFILE FOR LOPINAVIR AND RITONAVIR

505(b)(2) Clinical Trials for Lopinavir And Ritonavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.

All Clinical Trials for Lopinavir And Ritonavir

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004578 ↗	ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects	Completed	Abbott	Phase 1/Phase 2	1997-11-01	To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
NCT00006144 ↗	A Study of HIV-Disease Development in Aging	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2000-10-01	The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00014937 ↗	Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.

Clinical Trial Conditions for Lopinavir And Ritonavir

Condition Name

Condition Name for Lopinavir And Ritonavir
Intervention	Trials
HIV Infections	139
COVID-19	36
HIV	35

Condition MeSH

Condition MeSH for Lopinavir And Ritonavir
Intervention	Trials
HIV Infections	194
COVID-19	69
Acquired Immunodeficiency Syndrome	43

Clinical Trial Locations for Lopinavir And Ritonavir

Trials by Country

Trials by Country for Lopinavir And Ritonavir
Location	Trials
United States	755
Spain	88
Thailand	66
Canada	56
South Africa	54

Trials by US State

Trials by US State for Lopinavir And Ritonavir
Location	Trials
California	61
New York	55
Florida	42
Texas	40
Illinois	40

Clinical Trial Progress for Lopinavir And Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Lopinavir And Ritonavir
Clinical Trial Phase	Trials
Phase 4	90
Phase 3	76
Phase 2/Phase 3	24

Clinical Trial Status

Clinical Trial Status for Lopinavir And Ritonavir
Clinical Trial Phase	Trials
Completed	219
Terminated	30
Recruiting	29

Clinical Trial Sponsors for Lopinavir And Ritonavir

Sponsor Name

Sponsor Name for Lopinavir And Ritonavir
Sponsor	Trials
Abbott	55
National Institute of Allergy and Infectious Diseases (NIAID)	51
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	20

Sponsor Type

Sponsor Type for Lopinavir And Ritonavir
Sponsor	Trials
Other	503
Industry	147
NIH	86